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Abstract
Group A streptococci (GAS) are usually the predominant species in cases of bacteraemia caused by b haemolytic streptococci (BHS).
An increasing worldwide incidence of invasive disease from non-group A BHS has been reported. Little is known about the changing
trends in invasive disease caused by BHS in Australia. North Queensland has a relatively large indigenous population, who experience
signiﬁcantly higher rates of group A-related disease than the non-indigenous population. This prospective study examined changing
trends of disease from large colony BHS that group with A, B, C and G antisera over a 14-year period at the single large tertiary refer-
ral hospital in the area. We identiﬁed 392 bacteraemic episodes caused by BHS. GAS were most commonly isolated (49%), with
adjusted rates remaining stable over the period. There was a signiﬁcant increase in the incidence of non-neonatal bacteraemia caused
by group B streptococci (GBS) over the study period (r = 0.58; p 0.030), largely driven by infection in older, non-indigenous women.
Rates of bacteraemia caused by group C streptococci also experienced a modest, but signiﬁcant, increase over time (r = 0.67; p 0.009).
GAS, which had no predominant emm type, were seen most commonly in indigenous subjects (52%). Mortality rates ranged from 3.2%
(group G) to 10.3% (group C), with a rate of 7.9% associated with group A disease. The marked rise in GBS disease has been noted
worldwide, but the relatively low incidence in indigenous Australian patients has not been described before, despite the burden of well-
recognized risk factors for GBS disease within this group.
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Introduction
Reports of invasive b haemolytic streptococcal disease in
humans usually implicate the group A streptococcus (GAS)
as the major pathogen. Invasive GAS disease is characterized
by a variety of clinical presentations, including bacteraemia,
necrotizing fasciitis, myositis, scarlet fever and streptococcal
toxic shock syndrome (STSS). Since the 1980s, a resurgence
of GAS infection has been observed in many industrialized
countries, with an apparent increase in invasive disease [1].
Tropical northern Australia has been shown to have an
increased incidence of invasive GAS disease when compared
with temperate southern Australia [2–4]. The relative
predominance of the M1 and M3 serotypes in invasive GAS
disease has been noted in temperate southern Australia and
worldwide [5–7]. This, however, has not been demonstrated
in reports of invasive GAS disease from tropical regions such
as northern Australia, New Caledonia and Fiji, where differ-
ent and more diverse type distributions are seen, as deter-
mined by emm or vir typing [4,8,9].
The annual incidence of invasive GAS disease in North
America, has been variably reported to lie between 1.5 and
5.2 cases per 100 000 [10–13]. The reported incidence in
European populations appears to be similar [14]. However,
rates as high as 46 per 100 000 have been observed in
Native American populations [11]. A study from northern
Australia showed that indigenous Australians had a crude
incidence rate of 82.5 per 100 000 per year compared with
10.3 per 100 000 in non-indigenous patients [2].
Increasing incidence rates of invasive disease caused by
non-group A BHS, in particular those that express B, C or G
group antigens, have been reported worldwide [15–17].
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Group B streptococci (GBS), or S. agalactiae, has long been
associated with neonatal disease or maternal obstetric infec-
tions, being a common coloniser of the gastrointestinal and
vaginal tract. However, it is increasingly recognized as a sig-
niﬁcant and emerging pathogen beyond pregnancy-related or
neonatal disease, particularly in elderly patients or those with
signiﬁcant co-morbidities [18–22]. A large epidemiological
study in the US demonstrated a doubling of the annual inci-
dence of invasive GBS disease in non-pregnant adults from
3.6 per 100 000 in 1990 to 7.3 per 100 000 in 2007, an
effect thought not to be accounted for by an ageing popula-
tion alone [23]. Conversely, rates of neonatal disease appear
to have declined in the US population since the advent of
screening and prophylaxis in ante-natal care [24].
Isolates of b haemolytic streptococci (BHS) that group
with C or G antigens are traditionally divided according to
whether they form large or small colonies on blood agar.
Large colony group C or G BHS isolated from humans most
commonly belong to the species S. dysgalactiae subsp. equi-
similis, although may rarely belong to S. canis or S. equi subsp.
zooepidemicus. Small colony types belong to the anginosus
(or ‘milleri’) group of streptococci. Large colony group C or
G BHS were originally thought to be non-pathogenic com-
mensal ﬂora, but are increasingly recognized as signiﬁcant
human pathogens, with the potential for severe complica-
tions and a disease spectrum similar to S. pyogenes [16,25–
27]. A recent study examining invasive non-group A or B
streptococcal (NABS) disease in North America demon-
strated a comparable burden of disease to that caused by
invasive GAS infection [28].
There is little known about the impact of non-group A
BHS disease in Australia. Studies from the Northern Terri-
tory, where high rates of acute rheumatic fever and rheu-
matic heart diseases are seen within indigenous populations,
have shown that group G and C streptococci are more com-
monly cultured from pharyngeal throat swabs than GAS,
although GAS is more commonly isolated from skin lesions
[29,30]. A potential role for these organisms in the patho-
genesis of rheumatic fever has been suggested [31].
The purpose of this study was to examine trends in inva-
sive BHS disease over a 14-year period, from a region with a
high incidence of GAS disease and a signiﬁcant indigenous
population.
Methods
Data source
Prospectively entered data were extracted from a laboratory
bacteraemia database, which was established in 1996. This was
from a large tertiary level hospital in North Queensland, which
served a population that ranged from approximately 150 000
in 1996 to the current population of approximately 216 000
[32]. Between 7% and 10% of the population were of indige-
nous ethnicity during this period. All patients who had a posi-
tive blood culture for a b haemolytic streptococcus were
included. Non-haemolytic or a haemolytic streptococci were
not included. Repeatedly positive blood cultures with the same
organism identiﬁed within 28 days of initial isolation were con-
sidered as a single bacteraemic episode. Data that were
entered at the time of blood culture positivity included demo-
graphics, ethnicity, source and mortality at 28 days. Occupied
bed days for the hospital were obtained for the period under
study. Ethics approval was granted by the Townsville Health
Service District Human Ethics Committee.
Detection of bacteraemia
Over the 14-year period, two automated blood culture sys-
tems were used. A minimum of 20 mL of blood (two bot-
tles) from adults was collected. Between 1996 and 2000, the
Bactec system (Becton Dickinson, Franklin Lakes, NJ, USA)
was used and from 2001 till the present, the BacT/Alert sys-
tem (Biome´rieux Marcy l’Etoile, France) was used. All blood
cultures that signalled positive had a Gram stain performed
and were subcultured onto Columbia horse blood agar and
chocolate agar. These were incubated in air and CO2,
respectively, at 35C for up to 48 h.
Identiﬁcation of haemolytic streptococci
All organisms that demonstrated b haemolysis on blood agar
with a Gram stain resembling Gram-positive cocci in pairs or
chains had a catalase test performed. Catalase-negative, b hae-
molytic organisms resembling streptococci were then tested
for the presence of one of the following Lanceﬁeld surface
antigens: A, B, C, D, F and G. This was done using a Streptex
latex agglutination kit. Groups D and F or small colony group
C or G (i.e. anginosus group) haemolytic streptococci were
not included in this study. Typing of GAS was performed by
emm sequence typing according to protocols developed by
the US Centers for Disease Control and Prevention (http://
www.cdc.gov/ncidod/biotech/strep/protocols.htm). A small
number of isolates were typed by M serotyping.
Statistical analysis
Age was summarized using mean and standard deviation
(SD); 95% conﬁdence intervals (95% CI) were calculated for
observed mortality stratiﬁed by group. Pearson’s correlation
coefﬁcient (r) was used to assess time trends of streptococ-
cal bacteraemia frequency per 100 000 bed days between
1996 and 2009. Statistical analysis was conducted using SPSS
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version 18 (PASW; SPSS Inc., Chicago, IL, USA). p-values
<0.05 were considered statistically signiﬁcant.
Results
Over the 14-year study period, there were a total of 392
episodes of bacteraemia caused by BHS. Of these, there
were 191 Group A (49%), 110 Group B (28%), 29 Group
C (7%) and 62 Group G (16%) streptococci identiﬁed.
Patient demographics and mortality for each antigen group
are summarized in Table 1. The crude overall mortality
rate at 28 days after the initial bacteraemia was 6.1% (95%
CI = 4.0, 9.0). The commonest source of bacteraemia was
skin and soft tissue (41%), followed by osteoarticular
(4.6%), respiratory (4.6%) and genito-urinary (4.3%)
sources. Almost one-quarter (23%) of infections had no
clear source identiﬁed. Contributions from other sources
such as intravascular catheters (2.8%), the gastrointestinal
tract (1%), endocarditis (0.8%) or meningitis (0.5%), were
relatively uncommon. Profound immunosuppression (che-
motherapy-related neutropenia, haematological malignancy,
HIV infection, solid organ transplant or the use of pro-
longed high dose corticosteroids) was found in 4.6% of
cases; 3% were dialysis-related events and 8.7% occurred in
neonates.
Annual rates of bacteraemia for each antigen group
adjusted for occupied bed days are represented in Fig. 1.
An apparent increase in the rates of group B streptococcal
(GBS) bacteraemia was noted over the study period. These
were grouped into neonatal and non-neonatal cases.
Adjusted rates of GBS bacteraemia per year in each group
are represented in Fig. 2. Total numbers of GBS bactera-
emia within each age and ethnic group are shown in Fig. 3.
The increasing trend for group B (driven by non-neonatal
disease) and C bacteraemia over the study period was
found to be signiﬁcant (see Table 2). Among the 191 GAS
isolates, 132 were submitted for emm typing, with 63 differ-
ent types identiﬁed, the results of which are summarized in
Fig. 4.
TABLE 1. Demographic data for bacteraemic episodes by antigen group
Lanceﬁeld group antigen
A B C G All
Total episodes 191 (49%) 110 (28%) 29 (7%) 62 (16%) 392
Mean age (years) [SD] 45.04 [25.38] 43.73 [33.10] 43.45 [23.82] 43.56 [20.22] 48.39 [28.02]
Male (%) 46.60 39.09 48.28 66.13 47.70
Female (%) 53.40 60.91 51.72 32.26 52.04
Indigenous (%) 52.88 12.73 41.38 19.35 35.46
Non-indigenous (%) 43.98 83.64 55.17 74.19 60.71
Ethnicity not stated (%) 3.14 3.64 3.45 6.45 3.83
Deaths
Number 15 4 3 2 24
% [95% CI] 7.9 [4.5–12.6] 3.6 [1.0–9.1] 10.3 [2.2–27.4] 3.2 [0.4–11.2] –
CI, conﬁdence interval; SD, standard deviation.
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FIG. 1. Annual bacteraemia rate by antigen
group per 100 000 bed occupancy days.
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Discussion
Streptococcus pyogenes (GAS) remains the major aetiological
agent of invasive BHS disease within this population. This
study has shown that adjusted rates for GAS disease have
been stable over the last 14 years. Cyclical variations in inci-
dence are noted, and there was no apparent association
between the incidence of GAS disease and rainfall. As previ-
ously reported, invasive GAS disease is commoner in the
indigenous population and is more prevalent in tropical
northern Australia than in the more temperate southern
regions. This study conﬁrms that the indigenous population
is over-represented, comprising over 50% of those with GAS
bacteraemia, despite making up around 7% of the local popu-
lation. As has been previously reported from our region, a
wide distribution of emm types was seen with no predomi-
nant type [2]. The 28-day case fatality rate for GAS disease
in this study remains high, with a crude rate of 7.9%, which
is comparable to studies from temperate Australia [3],
although considerably higher rates have been reported from
North America and Europe [10,14]. However, bacteraemia
caused by group C streptococci, despite being encountered
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FIG. 2. Annual adjusted incidence of group B
streptococcal bacteraemia; neonatal and non-
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FIG. 3. Group B streptococcal bacteraemia
by age group and ethnicity.
TABLE 2. Time trends (1996–2009) for bacteraemia fre-
quency per 100 000 bed days
Group Correlation coefﬁcient (r) p value
A 0.03 0.920
B total 0.58 0.030
B (neonatal) 0.26 0.380
B (non-neonatal) 0.60 0.023
C 0.67 0.009
G 0.12 0.686
Signiﬁcant results shown in bold.
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the least frequently, had the highest mortality at 10.3%, a
ﬁnding that has been reported elsewhere [33]. However,
comparisons in mortality between the groups should be
treated with caution given the small sample sizes and con-
sequently large conﬁdence intervals.
The incidence of invasive GBS disease has been increasing
in this region, as also reported for other populations, partic-
ularly in North America [23,24]. Reasons for this are unclear
but an increase in the ageing population has been postulated
as a factor [34]. A sharp rise in the incidence of GBS bacter-
aemia in 2001 was seen, the reasons for which are unclear.
Although a change in automated blood culture systems was
implemented at that time, the rates of bacteraemia caused
by other BHS remained steady, implying that improved
detection seems an unlikely explanation. The study reported
here has demonstrated a previously unrecognized phenome-
non. Invasive GBS disease in this region disproportionately
affected non-indigenous older females. Within the group
aged 70 years or greater, there were no cases of GBS bac-
teraemia in indigenous patients. In comparison, 12.1% (11/
191) of GAS bacteraemia episodes occurred in indigenous
patients aged 70 years or more. Unexpectedly, indigenous
females were not over-represented within the GBS bactera-
emia group, despite the known high rates of chronic co-
morbidities in this population [35]. The mean age of indige-
nous female subjects with GBS bacteraemia was 25.9 years,
while that of non-indigenous females was 47.4 years. It
appears that GBS disease in indigenous women is almost
exclusively in those of child-bearing age. One possible expla-
nation might be that older indigenous women have acquired
a degree of protective immunity to the various GBS capsular
serotypes from exposure in earlier life, although this remains
speculative. Another explanation might be the lower life
expectancy of the indigenous population. For the period
1996–2001 the life expectancy at birth for an indigenous
male was 59 and 65 years for females, compared with the
total Australian population of 78 and 83 years, respectively
[36]. The gender imbalance in the non-indigenous group
might be explained by the difference in rectal carriage
between the sexes. Rates of GBS rectal colonization in the
Indigenous population are unknown, but there is no reason
to believe that GBS rectal colonization in the indigenous
population is reduced. Co-morbidities such as cirrhosis,
diabetes mellitus, peripheral vascular disease and chronic
renal failure are well recognized as risk factors for invasive
GBS disease [19,20]. There is also a disproportionately high
incidence of GBS disease in black populations in the US [24].
It appears counter-intuitive that, despite socio-economic
disadvantage and the well-described burden of co-morbid
disease in indigenous patients [35], GBS bacteraemia should
be seen so infrequently in our series within this population.
The overall incidence of group G BHS disease was stable
over the 14-year study period, in contrast to studies from
other parts of the world [16,33]. Invasive GGS disease was
relatively uncommon in the indigenous population and was
seen predominantly in non-indigenous males. We documented
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FIG. 4. emm types of 131 GAS isolates isolated from blood cultures.
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a modest, but signiﬁcant, increase in the incidence of GCS
bacteraemia during the study period. However, the distribu-
tion according to ethnicity was similar to group A disease, in
that a large proportion (41.4%) were of indigenous origin.
Limitations to this study are acknowledged. The data col-
lected were derived from a single centre only and would not
include cultures submitted to private laboratories. However,
the Townsville Hospital laboratory receives the majority of
blood culture specimens from hospitalized patients in the
area, including several regional centres. Only a relative
minority would be processed outside the public system, and
we believe a reasonably representative sample of the total
population was provided. We did not have access to detailed
clinical information for all included patients; because of this
some designations for the source of bacteraemia may be
unreliable or those classiﬁed as ‘unknown’ may have been
deﬁned more clearly on detailed assessment. Furthermore,
we could not ascertain the relative contribution of other
co-morbidities to the trends observed.
In summary, therefore, we have described the changing
trends of bacteraemia caused by BHS in North Queensland
over a 14-year period. GAS remained the predominant iso-
late with relatively stable rates over time. There has been a
signiﬁcant increase in the incidence of non-neonatal GBS and
GCS bacteraemia. However, the burden of invasive GBS dis-
ease was mainly seen in non-indigenous women. We believe
that the apparent low incidence of GBS bacteraemia in indig-
enous Australian patients, despite rising trends in the general
population and the signiﬁcant burden of invasive GAS disease
and other co-morbidities within this group, has not been
widely described. Further work examining trends in a larger
patient cohort, along with studies to better deﬁne GBS colo-
nization rates in the indigenous population, may provide use-
ful insights.
Transparency Declaration
This manuscript has not been published or submitted else-
where. All authors have seen and approved the manuscript
and have contributed signiﬁcantly to the work. There is no
funding source or conﬂict of interests.
References
1. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemo-
ther 2000; 45 (suppl): 3–12.
2. Norton R, Smith HV, Wood N, Siegbrecht E, Ross A, Ketheesan N.
Invasive group A streptococcal disease in North Queensland (1996–
2001). Indian J Med Res 2004; 119 (suppl): 148–151.
3. O’Grady KA, Kelpie L, Andrews RM et al. The epidemiology of inva-
sive group A streptococcal disease in Victoria, Australia. Med J Aust
2007; 186: 565–569.
4. Carapetis JR, Walker AM, Hibble M, Sriprakash KS, Currie BJ. Clinical
and epidemiological features of group A streptococcal bacteraemia in
a region with hyperendemic superﬁcial streptococcal infection. Epi-
demiol Infect 1999; 122: 59–65.
5. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group
A streptococcal infection in the USA. Lancet 1990; 336: 1167–1171.
6. Kiska DL, Thiede B, Caracciolo J et al. Invasive group A streptococcal
infections in North Carolina: epidemiology, clinical features, and
genetic and serotype analysis of causative organisms. J Infect Dis 1997;
176: 992–1000.
7. Carapetis J, Robins-Browne R, Martin D, Shelby-James T, Hogg G.
Increasing severity of invasive group A streptococcal disease in Aus-
tralia: clinical and molecular epidemiological features and identiﬁca-
tion of a new virulent M-nontypeable clone. Clin Infect Dis 1995; 21:
1220–1227.
8. Le Hello S, Doloy A, Baumann F et al. Clinical and microbial charac-
teristics of invasive Streptococcus pyogenes disease in New Caledonia,
a region in Oceania with a high incidence of acute rheumatic fever.
J Clin Microbiol 2010; 48: 526–530.
9. Steer AC, Magor G, Jenney AW et al. emm and C-repeat region
molecular typing of beta-hemolytic Streptococci in a tropical country:
implications for vaccine development. J Clin Microbiol 2009; 47: 2502–
2509.
10. Davies HD, McGeer A, Schwartz B et al. Invasive group A strepto-
coccal infections in Ontario, Canada. Ontario Group A Streptococcal
Study Group. N Engl J Med 1996; 335: 547–554.
11. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM,
Englender SJ. The changing epidemiology of invasive group A strepto-
coccal infections and the emergence of streptococcal toxic shock-like
syndrome. A retrospective population-based study. JAMA 1993; 269:
384–389.
12. O’Brien KL, Beall B, Barrett NL et al. Epidemiology of invasive group
a streptococcus disease in the United States, 1995–1999. Clin Infect
Dis 2002; 35: 268–276.
13. Zurawski CA, Bardsley M, Beall B et al. Invasive group A streptococ-
cal disease in metropolitan Atlanta: a population-based assessment.
Clin Infect Dis 1998; 27: 150–157.
14. Lamagni TL, Darenberg J, Luca-Harari B et al. Epidemiology of severe
Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008; 46:
2359–2367.
15. Farley MM, Harvey RC, Stull T et al. A population-based assessment
of invasive disease due to group B Streptococcus in nonpregnant
adults. N Engl J Med 1993; 328: 1807–1811.
16. Sylvetsky N, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Bac-
teremia due to beta-hemolytic Streptococcus group G: increasing
incidence and clinical characteristics of patients. Am J Med 2002; 112:
622–626.
17. Barnham MR, Weightman NC. Changing incidence of detected strep-
tococcal bacteraemia in North Yorkshire, England. Indian J Med Res
2004; 119 (suppl): 160–163.
18. Schuchat A. Group B streptococcus. Lancet 1999; 353: 51–56.
19. Edwards MS, Baker CJ. Group B streptococcal infections in elderly
adults. Clin Infect Dis 2005; 41: 839–847.
20. Jackson LA, Hilsdon R, Farley MM et al. Risk factors for group B
streptococcal disease in adults. Ann Intern Med 1995; 123: 415–420.
21. Domingo P, Barquet N, Alvarez M, Coll P, Nava J, Garau J. Group B
streptococcal meningitis in adults: report of twelve cases and review.
Clin Infect Dis 1997; 25: 1180–1187.
22. Colford JM Jr, Mohle-Boetani J, Vosti KL. Group B streptococcal bac-
teremia in adults. Five years’ experience and a review of the litera-
ture. Medicine (Baltimore) 1995; 74: 176–190.
CMI Harris et al. Streptococcal bacteraemia in North Queensland 1221
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1216–1222
23. Skoff TH, Farley MM, Petit S et al. Increasing burden of invasive group
B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect
Dis 2009; 49: 85–92.
24. Phares CR, Lynﬁeld R, Farley MM et al. Epidemiology of invasive
group B streptococcal disease in the United States, 1999–2005. JAMA
2008; 299: 2056–2065.
25. Carmeli Y, Ruoff KL. Report of cases of and taxonomic consider-
ations for large-colony-forming Lanceﬁeld group C streptococcal bac-
teremia. J Clin Microbiol 1995; 33: 2114–2117.
26. Lopardo HA, Vidal P, Sparo M et al. Six-month multicenter study on
invasive infections due to Streptococcus pyogenes and Streptococcus dys-
galactiae subsp. equisimilis in Argentina. J Clin Microbiol 2005; 43: 802–
807.
27. Brandt CM, Spellerberg B. Human infections due to Streptococcus dys-
galactiae subspecies equisimilis. Clin Infect Dis 2009; 49: 766–772.
28. Broyles LN, Van Beneden C, Beall B et al. Population-based study of
invasive disease due to beta-hemolytic streptococci of groups other
than A and B. Clin Infect Dis 2009; 48: 706–712.
29. McDonald MI, Towers RJ, Andrews RM, Benger N, Currie BJ, Cara-
petis JR. Low rates of streptococcal pharyngitis and high rates of pyo-
derma in Australian aboriginal communities where acute rheumatic
fever is hyperendemic. Clin Infect Dis 2006; 43: 683–689.
30. McDonald M, Towers RJ, Andrews RM, Carapetis JR, Currie BJ. Epide-
miology of Streptococcus dysgalactiae subsp. equisimilis in tropical com-
munities, Northern Australia. Emerg Infect Dis 2007; 13: 1694–1700.
31. Haidan A, Talay SR, Rohde M, Sriprakash KS, Currie BJ, Chhatwal
GS. Pharyngeal carriage of group C and group G streptococci and
acute rheumatic fever in an Aboriginal population. Lancet 2000; 356:
1167–1169.
32. Australian Bureau of Statistics. 2010. Available at: http://www.abs.gov.
au/websitedbs/D3310114.nsf/home/Home?opendocument (last accessed
30 March 2010).
33. Rantala S, Vuopio-Varkila J, Vuento R, Huhtala H, Syrjanen J. Clinical
presentations and epidemiology of beta-haemolytic streptococcal bac-
teraemia: a population-based study. Clin Microbiol Infect 2009; 15:
286–288.
34. Farley MM. Group B streptococcal disease in nonpregnant adults. Clin
Infect Dis 2001; 33: 556–561.
35. Zhao Y, Dempsey K. Causes of inequality in life expectancy between
Indigenous and non-Indigenous people in the Northern Territory,
1981–2000: a decomposition analysis. Med J Aust 2006; 184: 490–494.
36. Australian Institute of Health and Welfare. Indigenous mortality data.
2006. Available at: http://www.aihw.gov.au/indigenous/health/mortal-
ity.cfm (last accessed 27 April 2010).
1222 Clinical Microbiology and Infection, Volume 17 Number 8, August 2011 CMI
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1216–1222
